Semaglutide is doing two things at once in obese mice, and only one of them is the point.
A study published June 2 in the Proceedings of the National Academy of Sciences ↗ reports that the weight-loss drug semaglutide ↗, the molecule sold as Ozempic and Wegovy, stripped a meaningful amount of skeletal muscle off mice as it stripped their fat. The same paper then shows a way to keep the fat loss and hand the muscle back: block one enzyme that climbs with injury and age.
The muscle is part of what comes off
The concern is not new. GLP-1 receptor agonists like semaglutide are the most effective weight-loss drugs ever sold, but a growing body of work says some of the weight a patient loses is lean tissue, not just fat. Muscle is the tissue that keeps people mobile, steadies blood sugar between meals, and carries a large share of the body's day-to-day metabolism. Losing it is not a cosmetic side note.
The authors put numbers on that trade-off in a mouse model. Mice made obese on a high-fat diet and then given semaglutide lost a significant amount of muscle mass. Their muscles still squeezed normally on a bench test, so raw contractile function held, but the mass was gone.
The picture got stranger after an injury. When the researchers damaged a muscle and watched it heal, the obese mice laid down pathological calcium deposits in the tissue, the kind of mineralized scarring usually described in Duchenne muscular dystrophy, an inherited muscle-wasting disease. Semaglutide cut some of that calcified remodeling, which is good, but it also left the newly regrown muscle fibers smaller than they should have been. Helpful in one direction, harmful in the other.
One enzyme, two drugs
The fix targets an enzyme called 15-PGDH, short for 15-hydroxyprostaglandin dehydrogenase. The authors call it a gerozyme because its levels rise with age and injury. Its job is to break down prostaglandins, signaling lipids that, among other things, help muscle stem cells do their repair work. More 15-PGDH means fewer of those pro-repair signals.
So the team gave the mice a 15-PGDH inhibitor alongside semaglutide. The inhibitor woke up muscle stem cells, pushed the regenerating fibers back to a normal size, and recovered strength that semaglutide alone had left on the table. The combination, in the authors' framing, boosted muscle quality and force after injury without compromising weight loss. The fat kept coming off. The muscle came back.
That last clause is the load-bearing one. A drug that preserves muscle by blunting weight loss would defeat the purpose. This one appears to separate the two outcomes, lifting muscle while leaving the fat-loss curve alone, at least in mice.
What it does not yet show
This is a mouse study, and the usual cautions apply twice over. A 15-PGDH inhibitor that synergizes with semaglutide in a high-fat-diet mouse is a long way from a pill a patient takes next to a weekly injection. The work does not report human dosing, and the injury-and-repair model is a deliberately harsh test, not a stand-in for ordinary aging on a GLP-1 drug.
What it does is name a specific, druggable target for a problem the field has mostly managed by telling patients to lift weights and eat protein. 15-PGDH inhibitors are already in development for other muscle and tissue-repair indications, which makes the combination plausible rather than hypothetical.
Semaglutide acts through the GLP-1 receptor ↗; the rescue described here runs through muscle repair ↗ machinery the receptor never touches. The interesting drugs of the next few years may be the ones that ride alongside the GLP-1 class and clean up what it leaves behind.